Prelude Capital Management, LLC Arvinas, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $479,587 - $792,122	19,607 New	19,607 $521,000
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $214,078 - $312,778	-3,251 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$73.2 - $107.87 $256,126 - $377,437	-3,499 Reduced 51.84%	3,251 $267,000
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $36,270 - $50,556	600 Added 9.76%	6,750 $520,000
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $72,737 - $114,212	-1,250 Reduced 16.89%	6,150 $407,000
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $66,041 - $277,806	3,271 Added 79.22%	7,400 $628,000
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $10,828 - $17,116	-471 Reduced 10.24%	4,129 $97,000
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $137,448 - $261,004	4,600 New	4,600 $154,000
Q3 2019 Nov 14, 2019	SELL	$21.55 - $27.61 $3,577 - $4,583	-166 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $2,649 - $3,950	166 New	166 $4,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.